Clostri Shield 7 (Canada)

Manufacturer: Novartis

Clostridium Chauvoei-septicum-novyi-sordellii-perfringens Types C & D Bacterin-toxoid

For Use In Animals Only

Clostri Shield 7 Indications

For use in healthy cattle and sheep as an aid in the prevention of diseases caused by C. chauvoei (blackleg), C. septicum (malignant edema), C. novyi (black disease), C. sordellii (gas-gangrene), and C. perfringens Types B, C, and D (enterotoxemia). Although C. perfringens Type B is not a significant problem in North America the combination of Type C (beta) and Type D (epsilon) toxoid immunizes against disease caused by C. perfringens Type B.

Adjuvant

Proprietary dual component.

Directions

Shake well before using. For cattle and sheep, administer 2 mL subcutaneously. In accordance with Beef Quality Assurance guidelines, this product should be administered subcutaneously (under the skin) in the neck. Revaccinate in 2-4 weeks. Calves vaccinated prior to 3 months of age should be revaccinated at 4-6 months of age or at weaning. Safety and efficacy has been demonstrated in sheep as young as 2 months of age. Revaccinate annually or as recommended by your veterinarian.

Precautions

Store out of direct sunlight at 2°-7°C (35°-45°F). DO NOT FREEZE. Use entire contents when first opened. Do not vaccinate within 21 days prior to slaughter. Vaccination may cause swelling at the injection site and, in sheep, transient lameness. Anaphylactic reactions may occur. Symptomatic treatment: Epinephrine.

U.S. Vet. License No. 303

Novartis Animal Health US, Inc.; ©2007 Novartis; Registered trademark of Novartis AG.

Novartis Animal Health Canada Inc., Mississauga, Ontario, Canada L5N 1V9

1-800-387-6325

10 Doses	20 mL	334CA-02
50 Doses	100 mL

Nac No.

12310892